Aisling Capital Revenue and Competitors

Location

$307.9M

Total Funding

VC/PE

Industry

Estimated Revenue & Valuation

  • Aisling Capital's estimated annual revenue is currently $15M per year.(i)
  • Aisling Capital's estimated revenue per employee is $750,000
  • Aisling Capital's total funding is $307.9M.

Employee Data

  • Aisling Capital has 20 Employees.(i)
  • Aisling Capital grew their employee count by 0% last year.

Aisling Capital's People

NameTitleEmail/Phone
1
Founder and Senior AdvisorReveal Email/Phone
2
ControllerReveal Email/Phone
3
Director Investor Relations & MarketingReveal Email/Phone
4
Compliance Manager and Head HRReveal Email/Phone
5
PartnerReveal Email/Phone
6
Managing PartnerReveal Email/Phone
7
no titleReveal Email/Phone
8
Exec Admin to Steve Elms and Eric AguiarReveal Email/Phone
9
Administrative ProfessionalReveal Email/Phone
10
PrincipalReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$3.5M180%N/AN/A
#2
N/A19-21%N/AN/A
#3
$7.5M5721%N/AN/A
#4
$11830M3644%$1MN/A
#5
$7.5M4850%$48.1MN/A
#6
$15M12317%N/AN/A
#7
N/A8-88%N/AN/A
#8
N/A24-11%N/AN/A
#9
N/A1614%N/AN/A
#10
$7.5M5320%N/AN/A
Add Company

What Is Aisling Capital?

Aisling Capital is a dedicated life sciences private equity firm with $1 billion under management. Headquartered in New York, Aisling Capital invests in both private and public companies utilizing a wide variety of investment structures. The Aisling Capital team's combination of clinical, operational and financial experience allows the firm to identify, execute and realize investments across the life sciences industry.

keywords:N/A

$307.9M

Total Funding

20

Number of Employees

$15M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Aisling Capital News

2022-04-13 - OMERS quietly co-invested in Medical Knowledge Group ...

... participated in Novo Holdings' acquisition of Medical Knowledge Group from Court Square Capital and Aisling Capital, PE Hub has learned.

2022-04-13 - OEP already closed 12 platform deals out of new $2.75bn ...

The purchase of the analytics-driven drug commercialization platform from Court Square Capital and Aisling Capital was announced by Novo...

2022-03-30 - Shorla Oncology Appoints Dennis Purcell as Chairman of the ...

Prior to Aisling Capital, Purcell served as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht &...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2.1M20-46%$25.1M
#2
$2M200%N/A
#3
$3.5M20-31%N/A
#4
$2M205%N/A
#5
$2M20-13%N/A